Ibrance decided for the health insurance benefit while Olita Tab to be decided later after Phase III clinical trial
The patient sharing amount for Pfizer Pharmaceuticals Korea’s Ibrance Cap(palbociclib) will be reduced from KRW 5 million to KRW 150 thousand with approval of the national health insurance service(NHIS).
Hanmi Pharm’s Olita Tab(olmutinib) was decided to discuss about its health insurance benefit...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
